Lung cancers diagnosed at annual CT screening: volume doubling times
- PMID: 22454506
- PMCID: PMC3329268
- DOI: 10.1148/radiol.12102489
Lung cancers diagnosed at annual CT screening: volume doubling times
Erratum in
- Radiology. 2012 Jul;264(1):306
Abstract
Purpose: To empirically address the distribution of the volume doubling time (VDT) of lung cancers diagnosed in repeat annual rounds of computed tomographic (CT) screening in the International Early Lung Cancer Action Program (I-ELCAP), first and foremost with respect to rates of tumor growth but also in terms of cell types.
Materials and methods: All CT screenings in I-ELCAP from 1993 to 2009 were performed according to HIPAA-compliant protocols approved by the institutional review boards of the collaborating institutions. All instances of first diagnosis of primary lung cancer after a negative screening result 7-18 months earlier were identified, with symptom-prompted diagnoses included. Lesion diameter was calculated by using the measured length and width of each cancer at the time when the nodule was first identified for further work-up and at the time of the most recent prior screening, 7-18 months earlier. The length and width were measured a second time for each cancer, and the geometric mean of the two calculated diameters was used to calculate the VDT. The χ(2) statistic was used to compare the VDT distributions.
Results: The median VDT for 111 cancers was 98 days (interquartile range, 108). For 56 (50%) cancers it was less than 100 days, and for three (3%) cancers it was more than 400 days. Adenocarcinoma was the most frequent cell type (50%), followed by squamous cell carcinoma (19%), small cell carcinoma (19%), and others (12%). Lung cancers manifesting as subsolid nodules had significantly longer VDTs than those manifesting as solid nodules (P < .0001).
Conclusion: Lung cancers diagnosed in annual repeat rounds of CT screening, as manifest by the VDT and cell-type distributions, are similar to those diagnosed in the absence of screening.
Figures
Similar articles
-
Lung cancer screening intervals based on cancer risk.Lung Cancer. 2020 Nov;149:113-119. doi: 10.1016/j.lungcan.2020.09.013. Epub 2020 Sep 23. Lung Cancer. 2020. PMID: 33007677
-
Lung Cancers Manifesting as Part-Solid Nodules in the National Lung Screening Trial.AJR Am J Roentgenol. 2017 May;208(5):1011-1021. doi: 10.2214/AJR.16.16930. Epub 2017 Feb 28. AJR Am J Roentgenol. 2017. PMID: 28245151 Clinical Trial.
-
CT Screening for Lung Cancer: Nonsolid Nodules in Baseline and Annual Repeat Rounds.Radiology. 2015 Nov;277(2):555-64. doi: 10.1148/radiol.2015142554. Epub 2015 Jun 23. Radiology. 2015. PMID: 26101879 Free PMC article.
-
Retrospective review of lung cancers diagnosed in annual rounds of CT screening.AJR Am J Roentgenol. 2014 Nov;203(5):965-72. doi: 10.2214/AJR.13.12115. Epub 2014 Sep 23. AJR Am J Roentgenol. 2014. PMID: 25247825 Review.
-
CT screening for lung cancer: past and ongoing studies.Semin Thorac Cardiovasc Surg. 2005 Summer;17(2):99-106. doi: 10.1053/j.semtcvs.2005.05.002. Semin Thorac Cardiovasc Surg. 2005. PMID: 16087075 Review.
Cited by
-
Comparison of lung cancer occurring in fibrotic versus non-fibrotic lung on chest CT.J Transl Med. 2024 Jan 16;22(1):67. doi: 10.1186/s12967-023-04645-y. J Transl Med. 2024. PMID: 38229113 Free PMC article.
-
Prediction of subsolid pulmonary nodule growth rate using radiomics.BMC Med Imaging. 2023 Nov 7;23(1):177. doi: 10.1186/s12880-023-01143-x. BMC Med Imaging. 2023. PMID: 37936095 Free PMC article.
-
A spatio-temporal image analysis for growth of indeterminate pulmonary nodules detected by CT scan.Radiol Phys Technol. 2024 Mar;17(1):71-82. doi: 10.1007/s12194-023-00750-1. Epub 2023 Oct 27. Radiol Phys Technol. 2024. PMID: 37889460
-
Factors influencing the outcome of volumetry tools for pulmonary nodule analysis: a systematic review and attempted meta-analysis.Insights Imaging. 2023 Sep 23;14(1):152. doi: 10.1186/s13244-023-01480-z. Insights Imaging. 2023. PMID: 37741928 Free PMC article. Review.
-
Observational Study of the Natural Growth History of Peripheral Small-Cell Lung Cancer on CT Imaging.Diagnostics (Basel). 2023 Aug 1;13(15):2560. doi: 10.3390/diagnostics13152560. Diagnostics (Basel). 2023. PMID: 37568923 Free PMC article.
References
-
- Black WC. Computed tomography screening for lung cancer: review of screening principles and update on current status. Cancer 2007;110(11):2370–2384 - PubMed
-
- Bach PB. Overdiagnosis in lung cancer: different perspectives, definitions, implications. Thorax 2008;63(4):298–300 - PubMed
-
- Bach PB, Silvestri GA, Hanger M, Jett JR; American College of Chest Physicians. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):69S–77S - PubMed
-
- Day NE, Walter SD, Collette B. Statistical models of disease natural history: their use in the evaluation of screening programmes. In: Prorok PC, Miller AB, eds. Screening for cancer. I. General on evaluation of screening for cancer and screening for lung, bladder, and oral cancer. UICC Technical Report Series No 78. Geneva, Switzerland: Union for International Cancer Control, 1984; 55–70
-
- Morrison A. Screening in chronic disease. New York, NY: Oxford University Press, 1992
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
